A POC Clinical Trial for PTSD with a First-In-Class Vasopressin 1a Receptor Antagonist
Technical Report,30 Sep 2015,29 Sep 2016
Azevan Pharmaceuticals, Inc. Bethlehem United States
Pagination or Media Count:
In this reporting period, year 1 of the project, the major milestones met included obtaining approval from the responsible local Institutional Review Board IRB and the Human Research Protections Office HRPO the hiring and training of personnel that will work on the clinical trial and the acquisition of equipment and methods set-up. In the second year of the project, the major objective will be to recruit and enroll subjects to participate in the clinical study that will test the effect of SRX246, a first-in-class vasopressin 1a receptor antagonist, as a potential new treatment for PTSD.
- Medicine and Medical Research